**DRUG NAME:** Carboplatin  

**SYNONYM(S):** CBDCA, JM8, NSC 241240  

**COMMON TRADE NAME(S):** PARAPLATIN®, PARAPLATIN-AQ®  

**CLASSIFICATION:** Alkylating agent

*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.*

**MECHANISM OF ACTION:**

Carboplatin is an analog of cisplatin. Like cisplatin, it contains a platinum atom surrounded in a plane by two ammonia groups and two other ligands in the *cis* position. The other two ligands in carboplatin are present in a ring structure rather than as two chloride atoms in cisplatin. This difference makes carboplatin more stable and has less nephrotoxicity, neurotoxicity, ototoxicity and emetogenesis. The exact mechanism of action of carboplatin is not known. Carboplatin undergoes intracellular activation to form reactive platinum complexes which are believed to inhibit DNA synthesis by forming interstrand and intrastrand cross-linking of DNA molecules. Carboplatin is a radiation-sensitizing agent. It is cell cycle-phase nonspecific.

**PHARMACOKINETICS:**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interpatient variability</td>
<td>2- to 3-fold variability in AUC with BSA-based dosing. Variability can be reduced with Calvert AUC-based dosing formula.</td>
</tr>
<tr>
<td>Oral Absorption</td>
<td>poorly absorbed; oral route not used clinically</td>
</tr>
<tr>
<td>Intraperitoneal Absorption</td>
<td>peak plasma level within 2-4 h after intraperitoneal instillation with 65% of dose absorbed over 4 h of dwelling</td>
</tr>
<tr>
<td>Distribution</td>
<td>widely distributed, mostly in kidney, liver, skin, tumour tissue; also in erythrocytes cross blood brain barrier? yes volume of distribution ultrafilterable platinum*: 17 ± 2 L/1.73 m² plasma protein binding carboplatin: minimal2,11 platinum: 87%,2,12</td>
</tr>
<tr>
<td>Metabolism</td>
<td>undergoes intracellular hydrolysis to form reactive platinum complexes active metabolite(s) platinum complexes inactive metabolite(s) no information found</td>
</tr>
<tr>
<td>Excretion</td>
<td>renal excretion via glomerular filtration; extensively removed by hemodialysis. terminal half life 5.8 ± 1.6 days (total platinum*)1,10 platinum elimination from erythrocytes: 12 days clearance 1.38 ± 0.36 L/h/1.73 m² (total platinum*)10</td>
</tr>
<tr>
<td>Gender</td>
<td>no information found</td>
</tr>
<tr>
<td>Elderly</td>
<td>clearance may be reduced due to age-related renal function impairment2,11</td>
</tr>
<tr>
<td>Children</td>
<td>similar to adults6,13</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>no information found</td>
</tr>
</tbody>
</table>

Adapted from reference² unless specified otherwise.

*Ultrafilterable platinum consists of carboplatin and free carboplatin metabolites; total platinum consists of protein bound and free platinum. Pharmacokinetics of ultrafilterable platinum is clinically more useful as only free platinum species are cytotoxic.²
USES:

**Primary uses:**
- Brain tumours
- Endometrial cancer
- Germ cell tumours
- Head and neck cancer
- *Ovarian cancer*

**Other uses:**
- Bladder cancer
- Breast cancer
- Cervical cancer
- Ewing's sarcoma
- Leukemia, acute lymphocytic
- Lung cancer, non-small cell
- Lung cancer, small cell
- Lymphoma, non-Hodgkin's
- Melanoma
- Neuroblastoma
- Osteosarcoma
- Rhabdomyosarcoma
- Retinoblastoma
- Testicular cancer
- Wilms' tumour

*Health Canada Therapeutic Products Programme approved indication

SPECIAL PRECAUTIONS:

**Contraindication:** Manufacturer states that carboplatin is contraindicated in patients with known hypersensitivity to carboplatin, other platinum agents (eg, cisplatin) or mannitol. However, with appropriate precautions, rechallenging with carboplatin or switching to cisplatin has been tolerated by some patients with hypersensitivity reactions to carboplatin.

**Geriatrics:** Incidence of peripheral neuropathy is increased and myelosuppression may be more severe in patients older than 65 years of age. In addition, elderly patients are more likely to have age-related renal function impairment, which may require dosage reduction and careful monitoring of blood counts.

**Prior exposure to cisplatin:** increases the risk and severity of toxicities (eg, myelosuppression, nausea, vomiting, peripheral neuropathy, ototoxicity).

**Carcinogenicity:** has not been fully studied, but drugs with similar mechanisms of action and mutagenicity have been reported to be carcinogenic.

**Mutagenicity:** mutagenic in both in vitro and in vivo studies.

**Fertility:** may cause gonadal suppression (amenorrhea, azoospermia) which is generally related to dose and length of therapy and may be irreversible.

**Pregnancy:** FDA Pregnancy Category D. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (eg, if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

**Breastfeeding** is not recommended due to the potential secretion into breast milk.
SIDE EFFECTS:

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.

<table>
<thead>
<tr>
<th>ORGAN SITE</th>
<th>SIDE EFFECT</th>
</tr>
</thead>
<tbody>
<tr>
<td>allergy/immunology</td>
<td>hypersensitivity (2-30%)&lt;sup&gt;18-20&lt;/sup&gt;</td>
</tr>
<tr>
<td>auditory/hearing</td>
<td>ototoxicity (tinnitus, visual and taste disturbances) (1%)</td>
</tr>
<tr>
<td>blood/bone marrow</td>
<td>anemia (71%)</td>
</tr>
<tr>
<td>febrile neutropenia</td>
<td>leukopenia (severe 14%); nadir 21 days, recovery 30 days&lt;sup&gt;11&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>neutropenia (severe 18%); nadir 21-28 days, recovery 35 days&lt;sup&gt;11&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>thrombocytopenia (severe 25%); nadir 21 days, recovery 30 days&lt;sup&gt;11&lt;/sup&gt;</td>
</tr>
<tr>
<td>constitutional symptoms</td>
<td>asthenia (8%)</td>
</tr>
<tr>
<td>dermatology/skin</td>
<td>extravasation hazard: nonvesicant</td>
</tr>
<tr>
<td></td>
<td>alopecia (3%)</td>
</tr>
<tr>
<td>gastrointestinal</td>
<td>emetogenic potential: high moderate</td>
</tr>
<tr>
<td></td>
<td>constipation (6%)</td>
</tr>
<tr>
<td></td>
<td>diarrhea (6%)</td>
</tr>
<tr>
<td></td>
<td>nausea (15%)</td>
</tr>
<tr>
<td></td>
<td>vomiting (64%)</td>
</tr>
<tr>
<td>hepatic</td>
<td>elevated alkaline phosphatase (24%)</td>
</tr>
<tr>
<td></td>
<td>elevated AST (15%)</td>
</tr>
<tr>
<td></td>
<td>elevated bilirubin (5%)</td>
</tr>
<tr>
<td>infection</td>
<td>infections (4%)</td>
</tr>
<tr>
<td>metabolic/laboratory</td>
<td>hypocalcemia (22%)</td>
</tr>
<tr>
<td></td>
<td>hypomagnesemia (29%)</td>
</tr>
<tr>
<td></td>
<td>hypokalemia (20%)</td>
</tr>
<tr>
<td></td>
<td>hyponatremia (29%)</td>
</tr>
<tr>
<td></td>
<td>increased BUN (14%)</td>
</tr>
<tr>
<td></td>
<td>increased uric acid (5%)</td>
</tr>
<tr>
<td>neurology</td>
<td>CNS symptoms (5%)&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>peripheral neuropathy (4%)</td>
</tr>
<tr>
<td>ocular/visual</td>
<td>visual disturbances (rare)&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>pain</td>
<td>abdominal pain (17%)</td>
</tr>
<tr>
<td>renal/genitourinary</td>
<td>acute renal failure (rare)&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>decreased creatinine clearance (27%)</td>
</tr>
<tr>
<td></td>
<td>increased serum creatinine (6%)</td>
</tr>
<tr>
<td>syndromes</td>
<td>hemolytic-uremic syndrome (rare)</td>
</tr>
</tbody>
</table>

Adapted from reference<sup>12</sup> unless specified otherwise.
**Myelosuppression** is the dose-limiting toxicity, usually manifested as thrombocytopenia and less commonly as leukopenia, neutropenia and anemia. Risk factors include prior cytotoxic therapy (especially cisplatin), poor performance status, old age, impaired renal function and concurrent myelosuppressive therapy. Myelosuppression is dose dependent, closely related to the renal clearance of carboplatin, and minimized by using the Calvert AUC-based dosing formula. Anemia is more common with increased carboplatin exposure and blood transfusions may be needed during prolonged carboplatin therapy (eg, more than 6 cycles).

**Hypersensitivity** has been reported in 2% of patients receiving carboplatin alone and in 9-30% patients receiving carboplatin with other cytotoxic drugs. Reactions are similar to those seen with other platinum agents (eg, cisplatin) and include anaphylaxis and anaphylactoid reactions. Symptoms may vary in severity and include pruritus, rash, palmar erythema, fever, chills, rigor, swelling (face, tongue, infusion arm), GI upset, dyspnea, wheezing, tachycardia, and hypertension or hypotension. Reactions can develop during or several hours to days after carboplatin administration. The risk of reactions increases with repeated exposure to platinum agents, particularly after 7 courses of carboplatin or receiving the second course of carboplatin after prior platinum therapy. The hypersensitivity appears to be mainly an IgE-mediated type I immediate reaction but may also involve direct histamine release. Some reactions may also be due to the mannitol present in some carboplatin formulations. Management includes prompt treatment of anaphylaxis (see BCCA Hypersensitivity Guidelines) and oral diphenhydramine 25-50 mg every 4-6 hours for minor delayed reactions. In some cases, carboplatin therapy may be continued with prophylactic corticosteroid and antihistamine and/or desensitization.

**Nausea and vomiting** usually begin within 6-12 hours after administration and may persist up to 24 hours or longer. Acute vomiting appears to be mediated by local GI and central serotonin mechanisms and is most common in patients with prior emetogenic cytotoxic therapy or receiving concurrent emetogenic agents. The incidence and severity of vomiting may be reduced by prophylactic antiemetics. There is some evidence that the incidence of nausea and vomiting is reduced when carboplatin is given as a 24-hour continuous IV infusion or in divided doses over 5 consecutive days.

**Neurotoxicity** such as peripheral sensory neuropathy (eg, paresthesia) is less frequent or severe than with cisplatin. Peripheral neuropathy is more common in patients over 65, receiving prolonged carboplatin therapy or with prior cisplatin therapy. Patients with pre-existing cisplatin-induced peripheral neurotoxicity generally do not worsen during carboplatin therapy. Neurologic evaluations should be performed regularly.

**Nephrotoxicity**: is less common or severe than with cisplatin; concomitant IV hydration and diuresis generally are not needed with carboplatin. The risk and severity of nephrotoxicity are increased with high dose carboplatin regimen, especially when given concurrently with other nephrotoxic chemotherapy.

### INTERACTIONS:

<table>
<thead>
<tr>
<th>AGENT</th>
<th>EFFECT</th>
<th>MECHANISM</th>
<th>MANAGEMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>aminoglycosides (eg, amikacin, gentamycin, tobramycin)²</td>
<td>increased risk of carboplatin nephrotoxicity and ototoxicity</td>
<td>additive</td>
<td>use with caution during concurrent therapy</td>
</tr>
<tr>
<td>phenytoin²⁴,²⁵</td>
<td>decreased serum phenytoin level</td>
<td>possibly decreased absorption or increased metabolism of phenytoin</td>
<td>monitor serum phenytoin level carefully during and after carboplatin therapy; adjust phenytoin dose as needed</td>
</tr>
<tr>
<td>warfarin²⁵,²⁶</td>
<td>increased anticoagulant effect of warfarin</td>
<td>unknown; possibly decreased protein binding or decreased metabolism of warfarin</td>
<td>monitor INR carefully during and after carboplatin therapy; adjust warfarin dose as needed</td>
</tr>
</tbody>
</table>
SUPPLY AND STORAGE:

*Injection:* Hospira Healthcare Corporation supplies carboplatin as 50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL, and 600 mg/60 mL single use (preservative free) vials in a concentration of 10 mg/mL. Store at room temperature. Protect from light.

For basic information on the current brand used at the BC Cancer Agency, see Chemotherapy Preparation and Stability Chart in Appendix.

SOLUTION PREPARATION AND COMPATIBILITY:

For basic information on the current brand used at the BC Cancer Agency, see Chemotherapy Preparation and Stability Chart in Appendix.

Additional information:

Compatibility: consult detailed reference

PARENTERAL ADMINISTRATION:

<table>
<thead>
<tr>
<th>Administration</th>
<th>BCCA administration guideline noted in <strong>bold, italics</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcutaneous</td>
<td>no information found</td>
</tr>
<tr>
<td>Intramuscular</td>
<td>no information found</td>
</tr>
<tr>
<td>Direct intravenous</td>
<td>no information found</td>
</tr>
<tr>
<td><strong>Intermittent infusion</strong></td>
<td>over 30 min; can also be given over 15-60 min&lt;sup&gt;2,12&lt;/sup&gt;</td>
</tr>
<tr>
<td>Continuous infusion</td>
<td>over 24 h&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Intraperitoneal</strong></td>
<td><strong>infuse into abdominal cavity as rapidly as possible by gravity</strong>&lt;sup&gt;9,28,29&lt;/sup&gt;</td>
</tr>
<tr>
<td>Intrapleural</td>
<td>no information found</td>
</tr>
<tr>
<td>Intrathecal</td>
<td>no information found</td>
</tr>
<tr>
<td>Intra-arterial</td>
<td>investigative, 600 mg/m&lt;sup&gt;2&lt;/sup&gt; in NS 500 mL infused over 1 h&lt;sup&gt;15&lt;/sup&gt;</td>
</tr>
<tr>
<td>Intravesical</td>
<td>no information found</td>
</tr>
</tbody>
</table>

DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

**Adults:**

BCCA usual dose noted in **bold, italics**

Cycle Length:

**Intravenous:**

2-4 weeks: **AUC-based carboplatin dose IV for one dose on day 1**

Calculate carboplatin dose with Calvert formula:

Dose (mg) = AUC x (GFR + 25)<sup>7,8,30</sup>
BCCA usual dose noted in **bold, italics**

**Cycle Length:**

where AUC = 4-7, GFR obtained from nuclear renogram (preferred) or approximated by CrCl calculated from serum creatinine using the Cockcroft-Gault formula:\(^{31}\):

\[
\text{GFR (mL/min)} = \frac{\text{N} \times (140 - \text{Age}) \times \text{weight (kg)}}{\text{serum creatinine (µmol/L)}}
\]

where N = 1.04 for females and 1.23 for males

Estimated GFR (reported by lab as eGFR) or calculated creatinine clearance (using Cockcroft Gault formula) should be **capped** at 125 mL/min when used to calculate the *initial* dose of carboplatin using the Calvert Formula (AUC(GFR+25)).\(^{32}\)

Note that the Cockcroft-Gault formula overpredicts CrCl in certain conditions (eg, muscle wasting, obesity, ascites). Lean or ideal body weight may be used to correct for excess fat or fluid.\(^{33}\) Repeat renogram to modify dose if > 20% increase in serum creatinine during treatment.\(^{34,35}\)

Calvert AUC-based dosing formula is not recommended with GFR or CrCl < 20 mL/min.\(^{2,7}\)

3-4 weeks\(^{1,12}\): 300 mg/m\(^2\) (range 200-400 mg/m\(^2\)) IV for one dose on day 1

**Bone marrow transplant:**

higher doses are used for tumour ablation prior to bone marrow transplant, eg,

- 266-666 mg/m\(^2\)/day IV for 3 days
- 200-500 mg/m\(^2\)/day IV for 4 days
- 175-400 mg/m\(^2\)/day IV for 5 days\(^{22,36,37}\)

**Concurrent with radiation:**

investigational, 30 mg/m\(^2\) IV once daily on days 1-5 in weeks 1-4 has been used as radiosensitizer\(^3\)

**Dosage in myelosuppression:**

modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix 6 “Dosage Modification for Myelosuppression”.

**Dosage in renal failure:**

adjustment required when BSA-based dosing (mg/m\(^2\)) is used; the following is suggested:\(^{27,38}\)

<table>
<thead>
<tr>
<th>CrCl (mL/min)</th>
<th>Starting dose (mg/m(^2))</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;40</td>
<td>400</td>
</tr>
<tr>
<td>20-39</td>
<td>250</td>
</tr>
<tr>
<td>10-19</td>
<td>150</td>
</tr>
<tr>
<td>0-9</td>
<td>100</td>
</tr>
</tbody>
</table>

\[
\text{calculated creatinine clearance} = \frac{\text{N} \times (140 - \text{Age}) \times \text{weight in kg}}{\text{serum creatinine (µmol/L)}}
\]

*where N = 1.04 for females and 1.23 for males*
Carboplatin

BCCA usual dose noted in bold, italics

Cycle Length:
adjust subsequent dose according to hematological toxicity to previous
dose²,¹²,²⁷

Dosage in hepatic failure: no adjustment required

Dosage in dialysis:
- hemodialysis: • supplement with 50% of the dose after dialysis³⁸
  • In dialysis-dependent chronic renal failure, a fixed dose
    of 100 mg (previous platinum treatment) or 150 mg (no
    previous platinum treatment) may be used, with dialysis
    performed 24 h after carboplatin administration.³⁹
- peritoneal dialysis³⁸: dose as per GFR <10 mL/min (25% of the dose)
- continuous renal replacement therapy³⁸: 200 mg/m²

Children:
Cycle length:

Intravenous:
- 3-4 weeks: 400 mg/m² IV once daily for 2 consecutive days
  starting on day 1
  (total dose per cycle 800 mg/m²)⁴⁰
- 4 weeks⁵: 560 mg/m² IV for one dose on day 1
- 4 weeks: 80-216 mg/m² IV once daily for 5 consecutive days
  starting on day 1
  (total dose per cycle 400-1080 mg/m²)⁵,⁴¹

Some investigators calculate carboplatin dose with modified Calvert
formula: (GFR is obtained from nuclear renogram.⁴⁰,⁴²)

Dose (mg) = AUC x [(GFR x BSA)/1.73 + (15 x BSA)]

where GFR in mL/min/1.73 and AUC⁴⁰,⁴² = 6-7

or

Dose (mg) = AUC x (GFR + [0.36 x weight (kg)])

where AUC⁶,⁴³ = 2-7

Bone marrow transplant: higher doses are used for tumour ablation prior to bone marrow
transplant, eg,
- 100-800 mg/m²/day IV for 3 days
- 250-300 mg/m²/day IV for 4 days
- 250-350 mg/m²/day IV for 5 days⁵
REFERENCES: